BP-C1 in treatment of patients with stage IV breast cancer: A randomized, double-blind, placebo-controlled multicenter study and additional open-label treatment phase.
E12086 Background: The aims were to compare the efficacy and tolerability of a new benzene-poly-carboxylic acids complex with cis-diammineplatium (II) (BP-C1) versus equal looking placebo and to investigate the long-term tolerability of BP-C1 in treatment of patients with metastatic breast cancer. Methods: A randomized, double blind, placebo controlled multi-center study was performed. Patients allocated to placebo switches to BP-C1 after 32 days of treatment. Patients completed 32 days of treatment offers to continue BP-C1 open label for additional 32 days. Thirty patients were given daily intramuscular injection of 0.035 mg/kg bw BP-C1 or placebo in 32 days. NCI Bethesda (CTC-NCI), EORTC QOL-C30 and BR23 recorded at screening and after every 16 days of treatment. CT performed at screening and every 32-day. Results: The sum of target lesions increased 2.4% in the BP-C1 group and 14.3% in placebo. Only the increase in the placebo group was significant (p = 0.013). The difference between the group was significant in favor of BP-C1 (p = 0.04). Significant difference (p = 0.026) in favour of BP-C1 regarding RECIST classification. The sum of lesions slightly increased in the patient receiving 64 days of continuous BP-C1 treatment and 68.4% classified as responders. The Sum CTC-NCI toxicity score increased non-significantly in the BP-C1 group, but significantly in placebo (p = 0.05). The sum toxicity score reduces in the patients receiving 64 day of BP-C1 from 9.2 at screening to 8.9 at Day 48, but increased again to 10.6 during follow-up. “Breast cancer related pain and discomfort” and “Breast cancer treatment problem last week” were significantly reduced (p = 0.02) in the BP-C1 group and slightly increased in placebo. “Breast cancer treatment problem last week” was significantly reduced in the BP-C1 group (p = 0.02) and slightly increased in placebo. “Breast cancer related pain and discomfort”, Breast cancer treatment problem last week” and “Physical activity problem” significantly reduces during the 64 days of BP-C1 treatment (p ≤ 0.05) Conclusions: BP-C1 reduces the cancer growth, is well tolerated, improves quality-of-life and has few mainly mild AE.